2. Anti-infection NF-κB Apoptosis
  3. Bacterial IKK Ferroptosis
  4. Abietic acid

Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis.

For research use only. We do not sell to patients.

Abietic acid Chemical Structure

Abietic acid Chemical Structure

CAS No. : 514-10-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
5 mg USD 50 In-stock
10 mg USD 80 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Abietic acid Related Antibodies

Top Publications Citing Use of Products

View All IKK Isoform Specific Products:

View All Isoforms
IKK-α IKK-β IKK IKKε TBK1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis[1][2][3][4][5][6][7].
In Vitro

Abietic acid (0.8 μM, 24 h) inhibits the cell proliferation in in HUVECs, NSCLC and mouse macrophages, but increases tube formation, cell migration and the expression of p-p38 and p-ERK in HUVECs[2][3][6].
Abietic acid (0-50 μM, 24h) effectively arrested the cells in the G0/G1 phase through reducing the expression of cell cycle-related proteins[3].
Abietic acid (0-100 μM, 0.5 h or 1 h) binds directly to IKKβ and suppresses the IKKβ/NF-κB signaling pathway in NSCLC cells[3].
The structure of hepatocytes in acetaminophen (APAP) (HY-66005) (300 mg/kg, i.p., 13 h) + abietic acid (10, 20, 40mg /kg, i.p., 13 h) group is similar to that in APAP group, the area of inflammatory infiltration and tissue necrosis is significantly reduced, and the nucleolus is obvious in the liver of mice[5].
Abietic acid (20, 40, 80 μM, 13 h)significantly inhibits APAP-induced TNF-α, IL-1β expression and MDA and Fe2+ production, but significantly increases the expression of Nrf2 and HO-1 in liver cells[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Abietic acid Related Antibodies

Cell Viability Assay[2]

Cell Line: Human umbilical vein vascular endothelial cells (HUVECs)
Concentration: 0.4-25 μM
Incubation Time: 24 h
Result: Inhibited the proliferation of HUVECs in a dose-dependent manner.

Cell Migration Assay [2]

Cell Line: HUVECs
Concentration: 0.4 and 0.8 µM
Incubation Time: 24 h
Result: Resulted in HUVECs migration increases of 9.23 and 25.17% at 0.4 and 0.8 µM.

Cell Cycle Analysis[3]

Cell Line: NSCLC cells
Concentration: 0-50 μM
Incubation Time: 24 h
Result: Effectively arrested PC-9 and H1975 cells at the G0/G1 phase and down-regulated the expression of cyclin D1 and cdk4 in NSCLC cells.

Cell Viability Assay[6]

Cell Line: Mouse macrophages
Concentration: low concentrations (20, 40 and 80 µmol/L) and high concentrations (160 and 320 µmol/L)
Incubation Time: 26 h
Result: Decreased the viability of mouse macrophages at high concentrations and the concentration of IL-1β, TNF-α, IL-6 and MIP-2 which were induced by LPS in the cell culture medium of mouse macrophages.
In Vivo

Abietic acid (0.8 µM, daily for 10 days) exhibits accelerated wound healing in male ICR mouse model of cutaneous wounds[2].
Abietic acid (40 mg/kg, i.p., 6 or 24 h) improved survival and attenuates sepsis induced lung injury in mice[6].
Abietic acid (1.0 mg/kg, p.o., daily for 7 days) ameliorates the symptom of imiquimod (IMQ) (HY-B0180)-induced psoriasis-like inflammation and reconstructs the microbiota community composition in mice[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male ICR mouse model of cutaneous wounds (4-5 weeks of age)[2]
Dosage: 0.8 µM
Administration: treat wound daily, captured images on day 0, 2, 4, 6, 8, and 10
Result: Had an effect on wound closure in male ICR mouse model of cutaneous wounds.
Animal Model: Male C57BL/6 mice (24-30 g, 8-10 weeks old)[6]
Dosage: 40 mg/kg
Administration: i.p., 6 or 24 h
Result: Improved survival and attenuated sepsis induced lung injury in mice.
Animal Model: IMQ-induced psoriasis-like inflammation mice (7 weeks old, 16-18 g)
Dosage: 1.0 mg/kg
Administration: p.o., daily for 7 days
Result: Attenuated the imiquimod-induced psoriasis-like lesions and decreased PASI score of skin lesions in mice.
Molecular Weight

302.45

Formula

C20H30O2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]1(C2[C@@](CCC1)(C)[C@@]3([H])CCC(C(C)C)=CC3=CC2)C(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (330.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3063 mL 16.5317 mL 33.0633 mL
5 mM 0.6613 mL 3.3063 mL 6.6127 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 93.93%

COA (248 KB) RP-HPLC (232 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.3063 mL 16.5317 mL 33.0633 mL 82.6583 mL
5 mM 0.6613 mL 3.3063 mL 6.6127 mL 16.5317 mL
10 mM 0.3306 mL 1.6532 mL 3.3063 mL 8.2658 mL
15 mM 0.2204 mL 1.1021 mL 2.2042 mL 5.5106 mL
20 mM 0.1653 mL 0.8266 mL 1.6532 mL 4.1329 mL
25 mM 0.1323 mL 0.6613 mL 1.3225 mL 3.3063 mL
30 mM 0.1102 mL 0.5511 mL 1.1021 mL 2.7553 mL
40 mM 0.0827 mL 0.4133 mL 0.8266 mL 2.0665 mL
50 mM 0.0661 mL 0.3306 mL 0.6613 mL 1.6532 mL
60 mM 0.0551 mL 0.2755 mL 0.5511 mL 1.3776 mL
80 mM 0.0413 mL 0.2066 mL 0.4133 mL 1.0332 mL
100 mM 0.0331 mL 0.1653 mL 0.3306 mL 0.8266 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Abietic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Abietic acid514-10-3BacterialIKKFerroptosisIκB kinaseI kappa B kinase anti-proliferativeanti-inflammatoryanti-ferroptosisbacteriostaticcell cycle arrestinglipoxygenase inhibitionangiogenic potentialwound closureNSCLClung and liver injurypsoriasisgut microbiotaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Abietic acid
Cat. No.:
HY-N6871
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.